Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

1. Effect of sodium-glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial.International urology and nephrology · 2023
   Trial
2. Regulation of Proximal Tubule Phosphate Transport: New Partners, New Pathways.Cells · 2026
   Review
3. Metabolic Profiling of the EmDia Cohort by LC-MS Reveals Empagliflozin-Intake Associated Regulation of 1,5-anhydroglucitol and Urate.Proteomics · 2026
   Article
4. Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition.Frontiers in molecular biosciences · 2025
   Review
5. Galactosylated hydroxyl-polyamidoamine dendrimer targets hepatocytes and improves therapeutic outcomes in a severe model of acetaminophen poisoning-induced liver failure.Bioengineering & translational medicine · 2023
   Article
6. SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice.Biomedicines · 2022
   Review
7. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.Diabetes & metabolism journal · 2022
   Review
8. SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist.Frontiers in nephrology · 2022
   Review
9. Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter.Nature · 2022
   Article
10. A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors.Cureus · 2021
    Review
11. Distinct Cation Gradients Power Cholesterol Transport at Different Key Points in the Hedgehog Signaling Pathway.Developmental cell · 2020
    Article
12. A role for tubular NaAmerican journal of physiology. Renal physiology · 2020
    Article
13. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.Pflugers Archiv : European journal of physiology · 2020
    Review
14. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.Medicina (Kaunas, Lithuania) · 2019 · on this map
    Review
15. PDZK1-interacting protein 1 (PDZK1IP1) traps Smad4 protein and suppresses transforming growth factor-β (TGF-β) signaling.The Journal of biological chemistry · 2019
    Article
16. Recent advances in renal epithelial transport.American journal of physiology. Renal physiology · 2019
    Article
17. Inhibitor binding mode and allosteric regulation of NaNature communications · 2018
    Article
18. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.Diabetologia · 2018
    Review
19. Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.Molecular cancer · 2018
    Review
20. Novel and Unexpected Functions of SGLTs.Physiology (Bethesda, Md.) · 2017
    Review

Corrections and comments

• Commented on by
  Recent advances in renal epithelial transport.2019

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as